Several other analysts also recently weighed in on RMTI. HC Wainwright decreased their price objective on Rockwell Medical from $5.00 to $3.00 and set a “buy” rating for the company in a report on Tuesday, January 18th. Zacks Investment Research upgraded Rockwell Medical from a “sell” rating to a “hold” rating in a report on Thursday, March 17th.
RMTI stock opened at $0.34 on Thursday. The company has a debt-to-equity ratio of 5.21, a current ratio of 1.68 and a quick ratio of 1.49. The business has a 50-day moving average price of $0.37 and a 200 day moving average price of $0.41. The company has a market capitalization of $32.33 million, a P/E ratio of -1.01 and a beta of 1.09. Rockwell Medical has a 1-year low of $0.30 and a 1-year high of $1.06.
Rockwell Medical Company Profile (Get Rating)
Rockwell Medical, Inc operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores.
- Get a free copy of the StockNews.com research report on Rockwell Medical (RMTI)
- Limelight Networks Stock is a Speculative Turnaround Opportunity
- The Selloff In SiteOne Landscape Supply Is Overextended
- Camping World Confirms Support At Institutional Bottom
- What’s Next For Starbucks (NASDAQ: SBUX)?
- 3 Earnings Plays With Big Move Potential
Receive News & Ratings for Rockwell Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical and related companies with MarketBeat.com's FREE daily email newsletter.